S0441
SB-366791
≥98% (HPLC), powder
Synonyme(s) :
N-(3-Methoxyphenyl)-4-chlorocinnamide
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C16H14NO2Cl
Numéro CAS:
Poids moléculaire :
287.74
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderQuality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear
originator
GlaxoSmithKline
SMILES string
COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1
InChI
1S/C16H14ClNO2/c1-20-15-4-2-3-14(11-15)18-16(19)10-7-12-5-8-13(17)9-6-12/h2-11H,1H3,(H,18,19)/b10-7+
InChI key
RYAMDQKWNKKFHD-JXMROGBWSA-N
Gene Information
human ... TRPV1(7442)
Application
SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist:
- to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (AMG 9810)
- to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity
- to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1)
Biochem/physiol Actions
SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior.
Vanilloid receptor-1 (TRPV1) antagonist.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Mauricio Guzmán et al.
Immunology, 161(2), 148-161 (2020-07-24)
Dry eye disease (DED) is a highly prevalent ocular surface disorder with neuroimmune pathophysiology. Tear hyperosmolarity (THO), a frequent finding in affected patients, is considered a key element in DED pathogenesis, yet existing animal models are based on subjecting the
Elizete Maria Rita Pereira et al.
Neuropharmacology, 162, 107826-107826 (2019-10-28)
Capsaicin, an agonist of TRPV1, evokes intracellular [Ca2+] transients and glutamate release from perfused trigeminal ganglion. The spider toxin PnTx3-5, native or recombinant is more potent than the selective TRPV1 blocker SB-366791 with IC50 of 47 ± 0.18 nM, 45 ± 1.18 nM and 390 ± 5.1 nM in
SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain
Niiyama Y, et al.
British Journal of Anaesthesia, 102(2), 251-258 (2009)